oxelumab (RG4930) News - LARVOL Sigma

|||||||||| oxelumab (RG4930) / Roche, Genmab
Review, Journal: Occurrence of Fasciola (Digenea: Fasciolidae) Species in Livestock, Wildlife and Humans, and the Geographical Distribution of Their Intermediate Hosts in South Africa-A Scoping Review. (Pubmed Central) - Aug 10, 2022
The prevalence of Fasciola spp infection in livestock ranged from 9.1 to 37.67 %, with an estimated annual financial loss ranging from R44930.26-129901 in cattle production in the Eastern Cape province of South Africa. This review reaffirms the scarcity of information on the occurrence and burden of fasciolosis in South Africa, and further highlights the importance of future research covering all provinces of the country and assessing the public health significance of the disease in resource-poor livestock communities in the areas where the parasite is endemic.

|||||||||| Humira (adalimumab) / Eisai, AbbVie, oxelumab (RG4930) / Roche, Genmab
Preclinical, Journal, Head-to-Head: Head to head study of oxelumab and adalimumab in a mouse model of ulcerative colitis based on NOD/Scid IL-2Rγ mice reconstituted with peripheral blood mononuclear cells. (Pubmed Central) - Jan 28, 2022
These results suggest that oxelumab addresses the pro-inflammatory arm of inflammation while promoting the remodeling arm and that patients exhibiting elevated levels of OX40L may benefit from treatment with oxelumab. Keywords: Ulcerative colitis, NOD/Scid IL2-Rγ, NSG, anti-CD252 antibodies, oxelumab, inflammatory bowel disease.

||||||||||  oxelumab (RG4930) / Roche, Genmab
Trial completion:  A Study of RO4989991 in Patients With Allergic Rhinitis (clinicaltrials.gov) -  Jan 16, 2012
P1, N=24, Completed,  Sponsor: Hoffmann-La Roche
Keywords: Ulcerative colitis, NOD/Scid IL2-Rγ, NSG, anti-CD252 antibodies, oxelumab, inflammatory bowel disease. Recruiting --> Completed



	Diseases Companies Products Productz Mechanisms of Action Sites